{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Dependent+Neoplasms",
    "query": {
      "condition": "Hormone Dependent Neoplasms"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 30,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Dependent+Neoplasms&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T08:45:49.628Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02632045",
      "title": "Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "LEE-011",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa K Accordino",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 169,
      "start_date": "2016-03",
      "completion_date": "2022-01-04",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02632045"
    },
    {
      "nct_id": "NCT04861896",
      "title": "A Research Study for Latina Women With Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer, Breast",
        "Cancer-related Problem/Condition",
        "Quality of Life",
        "Hormone Dependent Neoplasms",
        "Adherence, Medication"
      ],
      "interventions": [
        {
          "name": "\"My Guide\" (psychoeducation & self-management program)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2021-04-01",
      "completion_date": "2023-11-07",
      "has_results": false,
      "last_update_posted_date": "2023-11-08",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04861896"
    },
    {
      "nct_id": "NCT05307328",
      "title": "SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushing's Syndrome I",
        "Cushing Disease Due to Increased ACTH Secretion",
        "Cortisol Excess",
        "Cortisol; Hypersecretion",
        "Cortisol Overproduction",
        "Ectopic ACTH Secretion"
      ],
      "interventions": [
        {
          "name": "SPI-62",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sparrow Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-01",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307328"
    },
    {
      "nct_id": "NCT07227233",
      "title": "Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.",
          "type": "DRUG"
        },
        {
          "name": "Treatment of physician's choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2026-03-31",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 1,
      "location_summary": "La Jolla, California",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07227233"
    },
    {
      "nct_id": "NCT05262400",
      "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PF-07220060 + PF-07104091 combination dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + PF-07220060 + letrozole dose expansion",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 192,
      "start_date": "2022-03-14",
      "completion_date": "2026-08-23",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05262400"
    },
    {
      "nct_id": "NCT03155997",
      "title": "Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Standard Adjuvant Endocrine Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5637,
      "start_date": "2017-07-12",
      "completion_date": "2029-05",
      "has_results": true,
      "last_update_posted_date": "2026-04-24",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 162,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Gilbert, Arizona + 104 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03155997"
    },
    {
      "nct_id": "NCT01220973",
      "title": "Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "atorvastatin calcium",
          "type": "DRUG"
        },
        {
          "name": "celecoxib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Rutgers, The State University of New Jersey",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "MALE",
        "summary": "18 Years to 120 Years · Male only"
      },
      "enrollment_count": 27,
      "start_date": "2009-02",
      "completion_date": "2014-11-18",
      "has_results": true,
      "last_update_posted_date": "2018-06-08",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • Camden, New Jersey • Hamilton, New Jersey + 1 more",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Camden",
          "state": "New Jersey"
        },
        {
          "city": "Hamilton",
          "state": "New Jersey"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01220973"
    },
    {
      "nct_id": "NCT00081159",
      "title": "Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Goserelin acetate",
          "type": "DRUG"
        },
        {
          "name": "Leuprolide acetate",
          "type": "DRUG"
        },
        {
          "name": "Zoledronic acid",
          "type": "DRUG"
        },
        {
          "name": "orchiectomy",
          "type": "PROCEDURE"
        },
        {
          "name": "strontium chloride Sr",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 80,
      "start_date": "2004-07",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2016-11-10",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 4,
      "location_summary": "Orlando, Florida • Wichita, Kansas • Houston, Texas + 1 more",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Marshfield",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081159"
    },
    {
      "nct_id": "NCT04553133",
      "title": "PF-07104091 as a Single Agent and in Combination Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer",
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07104091 monotherapy dose escalation",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + palbociclib + fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + palbociclib + letrozole",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 monotherapy dose expansion (ovarian)",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 monotherapy dose expansion (SCLC)",
          "type": "DRUG"
        },
        {
          "name": "PF-07104091 + Fulvestrant (post CDK4/6)",
          "type": "DRUG"
        },
        {
          "name": "PF-0704091 + Fulvestrant (post CDK4/6)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2020-09-16",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-06",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 17,
      "location_summary": "Clive, Iowa • Des Moines, Iowa • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Clive",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553133"
    },
    {
      "nct_id": "NCT00044291",
      "title": "Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasms, Hormone-dependent"
      ],
      "interventions": [
        {
          "name": "atamestane",
          "type": "DRUG"
        },
        {
          "name": "toremifene",
          "type": "DRUG"
        },
        {
          "name": "letrozole",
          "type": "DRUG"
        },
        {
          "name": "aromatase inhibition",
          "type": "DRUG"
        },
        {
          "name": "hormone therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "endocrine therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "antiestrogen therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Intarcia Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 865,
      "start_date": "2002-06",
      "completion_date": "2006-01",
      "has_results": false,
      "last_update_posted_date": "2015-07-31",
      "last_synced_at": "2026-05-22T08:45:49.628Z",
      "location_count": 17,
      "location_summary": "Lake Havasu City, Arizona • Tucson, Arizona • Greenbrae, California + 14 more",
      "locations": [
        {
          "city": "Lake Havasu City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Shores",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00044291"
    }
  ]
}